

VIA FACSIMILE TRANSMISSION

Date of Deposit: January 16, 2002

Attorney Docket No. 22058-521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Assistant Commissioner for Patents
Washington, DC 20231

TRANSMITTAL LETTER


Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Supplemental Response (4 pgs); and,
2. Certificate of Transmission (1 pg).

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 22058-521).

Date: January 16, 2002

Respectfully submitted,

Ivor R. Elrifji, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on January 16, 2002

Date


SignatureMARIE SULKEY

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MINTZ LEVIN
COHN FERRIS
GLOVSKY AND
POPEO PC

Boston
New York
Reston
Washington

One Financial Center
Boston, Massachusetts 02111
617 542 6000
617 542 2241 fax
www.mintz.com

OFFICIAL

FAX RECEIVED

Fax Cover Sheet

JAN 17 2001

GROUP 1600

DATE: January 16, 2002

FROM: David E. Johnson, Ph.D., J.D.
Direct Dial 617 348 1768
dejohnson@mintz.com

TO:

NAME	BUSINESS #	FAX #
J. Seharaseyong, Examiner U.S. Patent and Trademark Office	703-305-1112	703-305-7461 305-3592

RE:

US Patent Application No. 09/521,696

308-2742
305-1935

"Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity"

Genetics Institute Reference: GI5345

Our Reference: 22058-521

We are sending a total of 7 pages, including this cover sheet.

Please call us at 617 654 8024, if you experience any problems.

STATEMENT OF CONFIDENTIALITY

THE INFORMATION CONTAINED IN THIS FAX IS INTENDED FOR THE EXCLUSIVE USE OF THE ADDRESSEE AND MAY CONTAIN CONFIDENTIAL OR PRIVILEGED INFORMATION. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY FORM OR DISSEMINATION OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF THIS FAX WAS SENT IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY PHONE.
TRA 1618997v)